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Policy makers will need to consider if it has one, not only as an
adjunct to gFOBT screening, but also as a primary screening test
S
creening for colorectal cancer (CRC)
using gFOBT (guaiac based faecal
occult blood test) has been shown in
randomised controlled trials (RCTs) to
reduce CRC mortality.1–3 gFOBT testing is
endorsed as an option for CRC screening
in the United States4–7 and is being
implemented in the United Kingdom.
People with a positive gFOBT receive
colonoscopy to detect early cancers and
advanced adenomas that, if untreated,
might cause CRC mortality. Because
gFOBT has a high rate of false positive
results, however, gFOBT screening can
incur substantial cost and use of colono-
scopy resources. A method that could
determine which people with a positive
gFOBT have false positive results—and do
not need colonoscopy—would make
gFOBT screening more practical.
A study in this issue of Gut8 Fraser et al
(see p 1415) shows that doing iFOBT
(human haemoglobin immunochemical
based FOBT) in people with a positive
gFOBT will detect almost all clinically
important lesions in gFOBT positive
individuals, while reducing false positive
results and the need for colonoscopy. In
this study, both iFOBT and colonoscopy
were done in those with a positive gFOBT,
defined as one to four positive gFOBT
ovals (people with five or six positive
ovals were automatically referred for
colonoscopy). The sensitivity of iFOBT
among people with positive gFOBT was
95.9%, while specificity was 59.2%, result-
ing in a 30% reduction of colonoscopy
use. The mechanism by which iFOBT
achieves higher specificity than gFOBT
presumably is elimination of false posi-
tives that occur in guaiac based testing
from sources other than human haemo-
globin, like diet.
Learning that iFOBT may have a role in
a programme of gFOBT screening is
practical and important, but it raises a
larger question that will need to be sorted
out over time. Should iFOBT replace
gFOBT as the primary test in a pro-
gramme of FOBT screening? The authors
note that the unit cost for iFOBT is higher
than for gFOBT, but that is only one
consideration.8 Others include the
increased benefit that might be achieved,
additional costs (including false posi-
tives), and the public’s willingness to
pay for greater benefit.
The potential usefulness of iFOBT vs
gFOBT screening depends largely on the
‘‘absolute sensitivity’’ of each FOBT, a
question not addressed in this study that
assessed iFOBT sensitivity only among
those who already had a positive gFOBT.
Used in this way, iFOBT can never do
better than gFOBT.
What is the absolute sensitivity for
each FOBT? Obtaining absolute sensitiv-
ity for any FOBT is logistically difficult,
requiring administration of both the
FOBT and a ‘‘gold standard’’ exam (like
colonoscopy). In asymptomatic indivi-
duals the prevalence of CRC is so low,
roughly 1–3 per 1000, that thousands of
people need to be studied. In one report,
gFOBT sensitivity for CRC was about
30%9; in another it was 13%.10 The
different results might be explained by
use of centralised FOBT processing in the
former study (as is also done in the
current study, in RCTs, and in the UK
screening programme being implemen-
ted), while in the latter study processing
was done in each physician’s office.
While these are low values for absolute
sensitivity of gFOBT, they are high
enough, as shown in RCTs, to reduce
CRC mortality by 33% in a US1 trial and
by about 16% in two European trials.2 3
Some mortality reduction may be
achieved by repeated application of
FOBT in a programme of screening.
gFOBT screening is considered not only
an ‘‘option’’ for CRC screening, but when
combined with sigmoidoscopy, it may be
competitive, in terms of effectiveness,
with a programme of colonoscopy screen-
ing.11 12 This seeming paradox—that a less
sensitive test like FOBT might be as
effective or more effective than a ‘‘gold
standard’’ test like colonoscopy—can be
explained by considering how a ‘‘pro-
gramme’’ of screening works. If a test
with lower sensitivity at any one applica-
tion is applied repeatedly over time in a
programme of screening, it may result in
a higher ‘‘programme’’ sensitivity than
when a more sensitive test (like colono-
scopy) is applied less frequently, because
a more frequently applied test can detect
fast growing CRC that would be missed
by a less frequently applied test.11–13
If gFOBT is not simply ‘‘acceptable’’ but
perhaps is even competitive with colono-
scopy in some settings, then what would
be the impact of a better FOBT? The
absolute sensitivity of iFOBT in recent
studies has been shown to be roughly
60% for CRC,14–17 much higher than for
gFOBT. Even without new RCT data to
assess CRC mortality reduction, policy
decisions may be based on data about
the sensitivity and specificity of newer
tests, existing RCT results, and model-
ling.7 Policy makers will need to consider
whether iFOBT has a role not only as an
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Antioxidant supplements may be ineffective for the treatment or
prevention of organ failure in predicted severe acute pancreatitis
O
xygen-derived free radicals are
produced when a period of intra-
cellular anaerobic respiration is
followed by re-oxygenation. These extre-
mely reactive radicals combine with a
large number of different protein and
lipid molecules causing tissue damage
and cell injury. The normal defences
against such free radical attack include
the presence in the tissues of antioxidant
compounds and pathways of metabolism.
A lack of sufficient antioxidant reserve
during times of increased production of
free radicals leads to the state of oxidative
stress.
There has been increasing awareness
over the last 20 years of the role played by
oxidative stress in many inflammatory
illnesses. Acute pancreatitis is no excep-
tion and in several models it has been
demonstrated that oxygen-derived free
radicals are generated during acute pan-
creatitis. It has been suggested that free
radical generation, or the inability to
quench free radicals, is an important
factor in the pathogenesis of acute pan-
creatitis.1 However, a careful experimen-
tal study suggested that oxidative stress
alone cannot cause pancreatitis.2 It is
much more plausible that oxidative stress
may contribute to worsening of the local
inflammatory changes after onset of
pancreatitis.3–6 Some experimental studies
suggest that antioxidant therapy can
diminish tissue injury in acute pancreati-
tis.3 7 It is also clear that oxidative
mechanisms are an integral part of the
inflammatory response and oxidative
stress may contribute to pulmonary injury
in severe acute pancreatitis.8 9 Oxidative
stress is recognised as part of the patho-
physiology of adult respiratory distress
syndrome,10 and there is experimental
evidence that antioxidants can protect
against lung injury in acute pancreatitis.
There is a convincing body of evidence
that antioxidant blood levels diminish
during severe acute pancreatitis,11 12 and
that supplements of antioxidants can
prevent these falls in experimental3 7
and clinical13 pancreatitis. However, the
evidence of clinical benefit to support the
therapeutic use of antioxidants is sparse
and uncontrolled.
Given the supposed harmful nature of
oxidative stress, and observation of anti-
oxidant depletion in human pancreati-
tis,11-13, it has been postulated that the
harmful effects of oxidative stress in this
condition could be ameliorated by sup-
plementation with naturally occurring
antioxidants. Unfortunately there is little
published evidence to support this theory.
One randomised trial14 reported reduced
frequency of attacks of recurrent acute
pancreatitis, in a small study population
(20 patients). This study made no obser-
vations relevant to the treatment of
patients with severe acute pancreatitis.
A case controlled series from Manchester
(where the treatment rationale was
developed) demonstrated that although
antioxidant supplements could indeed
prevent the fall in blood levels seen in
severe acute pancreatitis, there was no
observed effect on clinical outcome.13
Until now, there has been no reliable
randomised trial that investigates the use
of antioxidants to reduce the severity of
complications in acute pancreatitis. In
this issue, Siriwardena and colleagues15
report just such a randomised controlled
trial (see page 1439).
Siriwardena et al.15 report a trial that
carefully selected patients who might be
expected to benefit from antioxidant
treatment. They were recruited to the
study within 72 hours of onset of pan-
creatitis and they had an APACHE-II
score .8. That is, only patients with
predicted severe acute pancreatitis were
included, and treatment was started as
early as possible. These patients are
relatively few, and recruitment in three
hospitals extended over 41 months.
Interim analyses were conducted by a
trial statistician at planned annual inter-
vals and patients were treated according
to the UK National Guidelines for the
Management of Acute Pancreatitis. This
trial therefore focuses on the patients
most at risk, who were managed to a high
standard of care. The authors are to be
congratulated on achieving a relatively
low mortality rate, below 10%, for these
potentially seriously ill patients.
Patients were randomised to receive a
placebo injection or a mixture of antiox-
idants (n-acetylcysteine, selenium, vitamin
C), by intravenous injection for 1 week.
The two groups were well matched except
that the active treatment group were older.
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